Brought to you by 
Ligand buys Neurogen for stock plus contingent value rights
22 Apr 2022
Executive Summary
Drug discovery player Ligand Pharmaceuticals is issuing stock to acquire publicly held Neurogen (small-molecule CNS drug candidates), which is also entitled to contingent value rights (CVRs). Based on ten-day stock average prior to deal announcement, the transaction is valued at $11.7mm, plus at least $7mm in potential earn-outs.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ligand buys Neurogen for stock plus contingent value rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice